Cardioprotective properties of fibrates - Which fibrate, which patients, what mechanism?

被引：41

作者：

Barter, PJ

Rye, KA

机构：

[1] Heart Res Inst, Camperdown, NSW 2050, Australia

[2] Univ Sydney, Heart Res Inst, Sydney, NSW 2006, Australia

[3] Univ Sydney, Dept Med, Sydney, NSW 2006, Australia

[4] Univ Melbourne, Dept Med, Melbourne, Vic, Australia

来源：

CIRCULATION | 2006年 / 113卷 / 12期

关键词：

editorials; cardiovascular diseases; cholesterol; lipoproteins; trials;

D O I：

10.1161/CIRCULATIONAHA.105.620450

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：1553 / 1555

页数：3

共 14 条

[1]

[Anonymous], BR MED J

[2] Effects of fibrates on serum metabolic parameters [J].

Elisaf, M .

CURRENT MEDICAL RESEARCH AND OPINION, 2002, 18 (05) :269-276

[3] HELSINKI HEART-STUDY - PRIMARY-PREVENTION TRIAL WITH GEMFIBROZIL IN MIDDLE-AGED MEN WITH DYSLIPIDEMIA - SAFETY OF TREATMENT, CHANGES IN RISK-FACTORS, AND INCIDENCE OF CORONARY HEART-DISEASE [J].

FRICK, MH ;

ELO, O ;

HAAPA, K ;

HEINONEN, OP ;

HEINSALMI, P ;

HELO, P ;

HUTTUNEN, JK ;

KAITANIEMI, P ;

KOSKINEN, P ;

MANNINEN, V ;

MAENPAA, H ;

MALKONEN, M ;

MANTTARI, M ;

NOROLA, S ;

PASTERNACK, A ;

PIKKARAINEN, J ;

ROMO, M ;

SJOBLOM, T ;

NIKKILA, EA .

NEW ENGLAND JOURNAL OF MEDICINE, 1987, 317 (20) :1237-1245

[4] HIGH-DENSITY LIPOPROTEIN CHOLESTEROL AND CARDIOVASCULAR-DISEASE - 4 PROSPECTIVE AMERICAN-STUDIES [J].

GORDON, DJ ;

PROBSTFIELD, JL ;

GARRISON, RJ ;

NEATON, JD ;

CASTELLI, WP ;

KNOKE, JD ;

JACOBS, DR ;

BANGDIWALA, S ;

TYROLER, HA .

CIRCULATION, 1989, 79 (01) :8-15

[5] Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study):: randomised controlled trial [J].

Keech, A ;

Simes, RJ ;

Barter, P ;

Best, J ;

Scott, R ;

Taskinen, MR ;

Forder, P ;

Pillai, A ;

Davis, T ;

Glasziou, P ;

Drury, P ;

Kesäniemi, YA ;

Sullivan, D ;

Hunt, D ;

Colman, P ;

d'Emden, M ;

Whiting, M ;

Ehnholm, C ;

Laakso, M .

LANCET, 2005, 366 (9500) :1849-1861

[6] JOINT EFFECTS OF SERUM TRIGLYCERIDE AND LDL CHOLESTEROL AND HDL CHOLESTEROL CONCENTRATIONS ON CORONARY HEART-DISEASE RISK IN THE HELSINKI HEART-STUDY - IMPLICATIONS FOR TREATMENT [J].

MANNINEN, V ;

TENKANEN, L ;

KOSKINEN, P ;

HUTTUNEN, JK ;

MANTTARI, M ;

HEINONEN, OP ;

FRICK, MH .

CIRCULATION, 1992, 85 (01) :37-45

[7] Low-density lipoprotein and high-density lipoprotein particle subclasses predict coronary events and are favorably changed by gemfibrozil therapy in the veterans affairs high-density lipoprotein intervention trial [J].

Otvos, JD ;

Collins, D ;

Freedman, DS ;

Shalaurova, I ;

Schaefer, EJ ;

McNamara, JR ;

Bloomfield, HE ;

Robins, SJ .

CIRCULATION, 2006, 113 (12) :1556-1563

[8] Relation of gemfibrozil treatment and lipid levels with major coronary events - VA-HIT: A randomized controlled trial [J].

Robins, SJ ;

Collins, D ;

Wittes, JT ;

Papademetriou, V ;

Deedwania, PC ;

Schaefer, EJ ;

McNamara, JR ;

Kashyap, ML ;

Hershman, JM ;

Wexler, LF ;

Rubins, HB .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 285 (12) :1585-1591

[9] Diabetes, plasma insulin, and cardiovascular disease - Subgroup analysis from the Department of Veterans Affairs High-Density Lipoprotein Intervention Trial (VA-HIT) [J].

Rubins, HB ;

Robins, SJ ;

Collins, D ;

Nelson, DB ;

Elam, MB ;

Schaefer, EJ ;

Faas, FH ;

Anderson, JW .

ARCHIVES OF INTERNAL MEDICINE, 2002, 162 (22) :2597-2604

[10] Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol [J].

Rubins, HB ;

Robins, SJ ;

Collins, D ;

Fye, CL ;

Anderson, JW ;

Elam, MB ;

Faas, FH ;

Linares, E ;

Schaefer, EJ ;

Schectman, G ;

Wilt, TJ ;

Wittes, J .

NEW ENGLAND JOURNAL OF MEDICINE, 1999, 341 (06) :410-418

← 1 2 →